Abbisko (HKG:2256) reported 55.2 million yuan in profit for 2025, rising from 28.3 million yuan in 2024, according to a Hong Kong bourse filing Monday.
Shares of the biopharmaceutical company fell nearly 1% in morning trade Tuesday.
Earnings per share stood at 0.09 yuan, compared with 0.04 yuan a year prior.
Revenue for the year was 612.1 million yuan, compared with 504 million yuan in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.